



HAL
open science

Ex vivo activity of the ACT new components pyronaridine and piperquine in comparison with conventional ACT drugs against isolates of Plasmodium falciparum.

Aurélie Pascual, Philippe Parola, Françoise Benoit-Vical, Fabrice Simon, Denis Malvy, Stéphane Picot, Pascal Delaunay, Didier Basset, Danièle Maubon, Bernard Faugère, et al.

► To cite this version:

Aurélie Pascual, Philippe Parola, Françoise Benoit-Vical, Fabrice Simon, Denis Malvy, et al.. Ex vivo activity of the ACT new components pyronaridine and piperquine in comparison with conventional ACT drugs against isolates of Plasmodium falciparum.. Malaria Journal, 2012, 11, pp.45. 10.1186/1475-2875-11-45 . pasteur-00836167

HAL Id: pasteur-00836167

<https://riip.hal.science/pasteur-00836167>

Submitted on 20 Jun 2013

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

RESEARCH

Open Access

Ex vivo activity of the ACT new components pyronaridine and piperazine in comparison with conventional ACT drugs against isolates of *Plasmodium falciparum*

Aurélien Pascual^{1,2}, Philippe Parola³, Françoise Benoit-Vical⁴, Fabrice Simon⁵, Denis Malvy⁶, Stéphane Picot⁷, Pascal Delaunay⁸, Didier Basset⁹, Danièle Maubon¹⁰, Bernard Faugère¹¹, Guillaume Ménard¹², Nathalie Bourgeois¹³, Claude Oeuvray¹⁴, Eric Didillon¹⁵, Christophe Rogier¹ and Bruno Pradines^{1,2*}

Abstract

Background: The aim of the present work was to assess i) *ex vivo* activity of pyronaridine (PND) and piperazine (PPQ), as new components of artemisinin-based combination therapy (ACT), to define susceptibility baseline, ii) their activities compared to other partner drugs, namely monodesethylamodiaquine (MDAQ), lumefantrine (LMF), mefloquine (MQ), artesunate (AS) and dihydroartemisinin (DHA) against 181 *Plasmodium falciparum* isolates from African countries, India and Thailand, and iii) *in vitro* cross-resistance with other quinoline drugs, chloroquine (CQ) or quinine (QN).

Methods: The susceptibility of the 181 *P. falciparum* isolates to the nine anti-malarial drugs was assessed using the standard 42-hours ³H-hypoxanthine uptake inhibition method.

Results: The IC₅₀ values for PND ranged from 0.55 to 80.0 nM (geometric mean = 19.9 nM) and from 11.8 to 217.3 nM for PPQ (geometric mean = 66.8 nM). A significant positive correlation was shown between responses to PPQ and PND responses ($\rho = 0.46$) and between PPQ and MDAQ ($\rho = 0.30$). No significant correlation was shown between PPQ IC₅₀ and responses to other anti-malarial drugs. A significant positive correlation was shown between responses to PND and MDAQ ($\rho = 0.37$), PND and LMF ($\rho = 0.28$), PND and QN ($\rho = 0.24$), PND and AS ($\rho = 0.19$), PND and DHA ($\rho = 0.18$) and PND and CQ ($\rho = 0.16$). All these coefficients of correlation are too low to suggest cross-resistance between PPQ or PND and the other drugs.

Conclusions: In this study, the excellent anti-malarial activity of PPQ and PND was confirmed. The absence of cross-resistance with quinolines and artemisinin derivatives is consistent with the efficacy of the combinations of PPQ and DHA or PND and AS in areas where parasites are resistant to conventional anti-malarial drugs.

Keywords: Malaria, *Plasmodium falciparum*, Anti-malarial, *In vitro*, Resistance, Pyronaridine, Piperazine

Background

During the past 20 years, many strains of *Plasmodium falciparum* have become resistant to chloroquine and other anti-malarial drugs [1]. This has prompted a search for an effective alternative anti-malarial drug

with minimal side effects. The emergence and spread of parasites resistant to anti-malarial drugs has caused an urgent need for novel compounds to be discovered and developed. One strategy for reducing the prevalence of malaria is the combinatorial use of drugs. The combination protects each drug from the development of resistance and reduces the overall transmission of malaria [2]. The official first-line anti-malarial policy is now artemisinin-based combination therapy (ACT) [3]. The artemisinin derivative causes rapid and effective reduction of the parasite biomass and gametocytes carriage,

* Correspondence: bruno.pradines@free.fr

¹Unité de Recherche en Biologie et Epidémiologie Parasitaires Unité de Recherche pour les Maladies Infectieuses et Tropicales Emergentes UMR-6236, Institut de Recherche Biomédicale des Armées, Allée du Médecin-colonel Jamot, BP 60109, 13262 Marseille Cedex, France
Full list of author information is available at the end of the article

while the partner drug, which has a longer duration of action, achieves effective clinical and parasitological cure. Different formulations of ACT were evaluated: artesunate-sulphadoxine-pyrimethamine [4], artesunate-amodiaquine [5], artemether-lumefantrine [6], artesunate-mefloquine [7], artesunate-chlorproguanil-dapsone [8], dihydroartemisinin-piperaquine [9] and artesunate-pyronaridine [10].

However, suspected decreased susceptibility of ACT or, at least, longer parasite clearance times have been described in Cambodia [11-14]. In addition, prior therapy by amodiaquine-containing ACT selected reduced response to monodesethylamodiaquine, suggested that amodiaquine-containing regimens may rapidly lose efficacy in Africa [15]. This emergence of parasite resistance to ACT indicates that novel compounds and combinations need to be discovered and developed.

The aim of the present work was to assess i) *ex vivo* activity of two recent ACT partner drugs, pyronaridine (PND) and piperaquine (PPQ) to define the susceptibility baseline, ii) comparison with standard components of ACT, such as monodesethylamodiaquine (the active metabolite of amodiaquine) (MDAQ), lumefantrine (LMF), mefloquine (MQ), artesunate (AS) or dihydroartemisinin (DHA), and iii) *in vitro* cross-resistance with other quinoline drugs, such as chloroquine (CQ) and quinine (QN).

Methods

Plasmodium falciparum isolates

In total, 181 *P. falciparum* isolates were collected between April 2008 and April 2010 from patients hospitalized in France with imported malaria from a malaria-endemic country (Angola, Benin, Burkina Faso, Cameroon, Comoros, Congo, Ivory Coast, Gabon, Gambia, Ghana, Guinea, India, Madagascar, Mali, Mozambique, Niger, Central African Republic, Senegal, Thailand, Togo, Zambia). Informed consent was not required for this study as the sampling procedures and testing are part of the French national recommendations for the care and surveillance of malaria. Venous blood samples were collected in Vacutainer[®] ACD tubes (Becton Dickinson, Rutherford, NJ, USA) before treatment and transported at 4°C from French hospitals located in Marseille, Toulouse, Bordeaux, Lyon, Montpellier, Nice, Toulon, Nimes or Grenoble, to the Institute of Biomedical Research of the French Army (IRBA) in Marseille within less than 72 hours of collection. The Case Report Form was provided at the same time as a paper copy or electronically.

Thin blood smears were stained using a RAL[®] kit (Réactifs RAL, Paris, France) and examined to determine the *P. falciparum* density and to confirm mono-infection. Parasitized erythrocytes were washed three times in

RPMI 1640 medium (Invitrogen, Paisley, UK), buffered with 25 mM HEPES and 25 mM NaHCO₃. If parasitaemia exceeded 0.8%, infected

erythrocytes were diluted to 0.5-0.8% with uninfected erythrocytes (human blood type A+) and re-suspended in RPMI 1640 medium supplemented with 10% human serum (Abcys S.A. Paris, France) to a haematocrit of 1.5%.

Drugs

PPQ, PND, DHA and AS were obtained from Shin Poong Pharm Co. (Seoul, Korea). CQ and QN were purchased from Sigma (Saint Louis, MO). MDAQ was obtained from the World Health Organization (Geneva, Switzerland), MQ from Roche (Paris, France) and LMF from Novartis Pharma (Basel, Switzerland). PPQ, QN, MDAQ, MQ, DHA and AS were dissolved first in methanol and then diluted in water to obtain final concentration ranging from 0.8 to 1,000 nM for PPQ, 5 to 3,200 nM for QN, 1.56 to 1,000 nM for MDAQ, 3.2 to 400 nM for MQ and 0.1 to 100 nM for DHA and AS. PND and CQ were dissolved and diluted in water in concentrations ranging between 0.15 to 100 nM for PND, 5 to 3,200 nM for CQ. LMF was dissolved and diluted in ethanol to obtain final concentration ranging from 0.5 to 310 nM.

Ex vivo assay

The new term '*ex vivo* susceptibility' is used to describe studies on fresh isolates, while the term of '*in vitro* susceptibility' should now refer to studies on strains of parasites, which have been either kept in culture for at least two to three generations or which have been cryo-preserved. For *ex vivo* isotopic microtests, 200 µl/well of the suspension of synchronous parasitized red blood cells (final parasitaemia, 0.5%; final haematocrit, 1.5%) were distributed in 96-well plates pre-dosed with anti-malarial drugs. Parasite growth was assessed by adding 1 µCi of tritiated hypoxanthine with a specific activity of 14.1 Ci/mmol (Perkin-Elmer, Courtaboeuf, France) to each well at time zero. The plates were then incubated for 42 hours in controlled atmospheric conditions that consisted of 10% O₂, 5% CO₂, and 85% N₂ at 37°C with a humidity of 95%. Immediately after incubation, plates were frozen and then thawed to lyse erythrocytes. The content of each well was collected on standard filter microplates (Uni-filter GF/B; Perkin-Elmer) and washed using a cell harvester (Filter-Mate Cell Harvester; Perkin-Elmer). Filter microplates were dried, and 25 µl of scintillation cocktail (Microscint O; Perkin-Elmer) was placed in each well. Radioactivity incorporated in nucleotides by the parasites was measured with a scintillation counter (Top Count; Perkin-Elmer).

Internal controls were used (testing of 3D7 and W2 *P. falciparum* clones maintained in continuous culture) in order to validate the results. All strains were synchronized twice with sorbitol before use [16].

Clonality was verified using PCR genotyping of polymorphic genetic markers *msp1*, *msp2*, and microsatellite loci [17,18].

The drug concentration that inhibits 50% of parasite growth (IC₅₀) was defined as the drug concentration corresponding to 50% of the incorporation of tritiated hypoxanthine by the parasite in the drug-free control wells. The IC₅₀ value was determined by non-linear regression analysis of log-based dose-response curves (Riasmart™, Packard, Meriden, USA).

Statistical analysis

Data of *ex vivo* susceptibility of *P. falciparum* parasites were analysed after logarithmic transformation and expressed as the geometric mean of the IC₅₀ and the 95% confidence interval (95% CI). Cross-resistance between the nine drugs was assessed by a pair-wise correlation of IC₅₀ values of all isolates and estimated by coefficient of correlation of Spearman (*rho*) (non-parametric test), coefficient of correlation of Pearson (*r*) (parametric test) and coefficient of determination (*r*²).

Results

One hundred and eighty one *P. falciparum* isolates were tested for their *ex vivo* susceptibility to PPQ, PND, CQ, QN, MQ, MDAQ, LMF, DHA and AS. The mean IC₅₀s for these nine anti-malarial drugs are presented in Table 1. The IC₅₀ values for PND ranged from 0.55 to 80.0 nM (geometric mean = 19.9 nM, 95% = CI 18.0-022.0) and from 11.8 to 217.3 nM for PPQ (geometric mean = 66.8 nM, 95% CI = 61.8-72.3). The distributions of the IC₅₀ for the nine anti-malarial drugs are presented in Figure 1.

In vitro cross-resistance was measured by pair-wise correlation of IC₅₀ values of 181 isolates (Table 2). A significant positive correlation was shown between responses to PPQ and PND responses (*rho* = 0.46; *P* < 0.00001) and between PPQ and MDAQ (*rho* = 0.30; *P* = 0.0001). No significant correlation was shown between PPQ IC₅₀ and responses to other anti-malarial drugs. A significant positive correlation was shown between responses to PND and MDAQ (*rho* = 0.37; *P* < 0.00001), LMF (*rho* = 0.28; *P* = 0.0002), QN (*rho* = 0.24; *P* = 0.0012), AS (*rho* = 0.19; *P* = 0.0108), DHA (*rho* = 0.18; *P* = 0.0173) and CQ (*rho* = 0.16; *P* = 0.0365). The highest coefficients of correlation were shown for correlation between responses to DHA and AS (*rho* = 0.84; *P* < 0.00001), LMF and MQ (*rho* = 0.58; *P* < 0.00001), CQ and MDAQ (*rho* = 0.51; *P* < 0.00001), LMF and DHA (*rho* = 0.46; *P* < 0.00001), LMF and AS (*rho* = 0.45; *P* < 0.00001) or CQ and QN (*rho* = 0.41; *P* < 0.00001).

Isolates with high IC₅₀ to at least one of the anti-malarial drug are listed in Table 3. One originated from Thailand with IC₅₀ = 71.5 nM for PND associated with IC₅₀ = 91.1 nM for PPQ, IC₅₀ = 1,131 nM for QN, IC₅₀ = 166 nM for MQ, IC₅₀ = 114 nM for LMF, IC₅₀ = 21.2 nM for DHA and IC₅₀ = 16.3 nM for AS.


Discussion

Ex vivo analysis of the susceptibility of *P. falciparum* isolates to anti-malarial drugs has three important attributes. This approach allows firstly to assay the response of clinical isolates to individual drugs that are unmodified by important host factors that influence drug efficacy *in vivo*. Secondly, the progressive decline in drug susceptibility of isolates from the same site may identify incipient resistance in the parasite population. Finally, strains with reduced anti-malarial susceptibilities can then be established in continuous culture to provide the material needed to investigate novel molecular

Table 1 Ex vivo susceptibility of the 181 isolates of *Plasmodium falciparum* to pyronaridine (PND), piperaquine (PPQ), chloroquine (CQ), quinine (QN), mefloquine (MQ), monodesethylamodiaquine (MDAQ), lumefantrine (LMF), dihydroartemisinin (DHA) and artesunate (AS)

Drugs	No	IC ₅₀ in nM						
		geometric mean	95% Confidence Interval	min	Q25	median	Q75	max
PND	176	19.9	18.0-22.0	0.55	15.0	19.4	32.1	80.0
PPQ	179	66.8	61.8-72.3	11.8	48.0	76.7	90.5	217.3
CQ	181	79.8	66.6-95.6	5.0	22.9	96.0	246.0	1918.0
QN	181	254.6	234.7-276.1	54.8	182.0	265.0	358.0	1131.0
MQ	181	15.5	13.6-17.6	3.0	8.9	15.8	29.7	166.0
MDAQ	181	22.1	19.1-25.6	1.5	11.8	22.6	43.3	240.0
LMF	181	7.3	6.1-8.8	0.25	5.5	8.0	17.7	114.0
DHA	181	1.3	1.2-1.5	0.10	0.9	1.4	2.4	21.2
AS	179	1.1	1.0-1.3	0.10	0.7	1.3	2.1	20.6

Min: IC₅₀ minimum Max: IC₅₀ maximum
 Q25: 1st quartile Q75: 3rd quartile



mechanisms of resistance as well as for tests of susceptibility to other anti-malarial agents.

The continued spread of *P. falciparum* drug resistance to monotherapies has forced a shift toward the use of ACT. Nevertheless, resistance to at least one component of many of the different formulations of ACT currently in clinical use has been documented, and it is feared that the widespread use of ACT will gradually reduce its clinical efficacy. Clinical failures or at least longer parasite clearance times have been described in Cambodia [12]. In addition, prior therapy by amodiaquine-containing ACT selected reduced response to monodesethylamodiaquine, suggested that amodiaquine-containing regimens may rapidly lose efficacy in Africa [15].

One hundred and eighty one *P. falciparum* strains were tested for their *in vitro* susceptibility to PPQ, PND, CQ, QN, MQ, MDAQ, LMF, DHA and AS. The IC₅₀ values for PND ranged from 0.55 to 80.0 nM (geometric mean = 19.9 nM, 95% CI = 18.0-22.0). These values are

in accordance with previous studies on *P. falciparum* strains (1.9-47.8 nM and 15-49 nM, respectively) [19,20] or in isolates from patients in Thailand cured with PND (geometric mean = 15.7 nM) or that recrudesced after PND treatment (geometric mean = 23.0 nM) [21] but higher than those found in isolates from Cameroon (geometric mean = 3.58 nM), Senegal (geometric mean = 3.8 nM and 4.52 nM), Gabon (geometric mean = 3.0 nM and 1.87 nM) [22-26] and in Indonesia (geometric mean = 1.92 nM) [27]. In addition, PND is also effective *in vitro* against *Plasmodium vivax* isolates (geometric mean = 2.58 nM) [27].

Antagonistic *in vitro* drug interactions between PND and artemisinin derivatives have been described [22,28,29]. Previous studies have demonstrated *in vitro* cross-resistance between PND and DHA or CQ, with coefficients of determination (r^2) of 0.84 and 0.19-0.46, respectively [19,21,23-25]. A low r^2 (0.20) was determined between PND and AS in *P. falciparum* strains

Table 2 Spearman correlation (rho) and Pearson correlation (r²) of *in vitro* responses of 181 isolates of *Plasmodium falciparum* to pyronaridine (PND), piperaquine (PPQ), chloroquine (CQ), quinine (QN), mefloquine (MQ), monodesethylamodiaquine (MDAQ), lumefantrine (LMF), dihydroartemisinin (DHA) and artesunate (AS)

		CQ	QN	MQ	DHA	AS	MDAQ	LMF	PND
QN	Rho	0,4143							
	p-value	< 0,00001							
	r ²	0.159							
MQ	Rho	-0,1254	0,1139						
	p-value	0,0936	0,128						
	r ²	0.020	0.008						
DHA	Rho	-0,1471	0,134	0,3164					
	p-value	0,0488	0,0729	< 0,00001					
	r ²	0.026	0.020	0.109					
AS	Rho	-0,1196	0,1291	0,364	0,8374				
	p-value	0,1109	0,0851	< 0,00001	< 0,00001				
	r ²	0.013	0.013	0.124	0.681				
MDAQ	Rho	0,5071	0,0997	-0,115	-0,1615	-0,0769			
	p-value	< 0,00001	0,1831	0,1243	0,0303	0,3074			
	r ²	0.227	0.012	0.014	0.028	0.005			
LMF	Rho	-0,1799	0,126	0,5821	0,4636	0,4533	-0,1451		
	p-value	0,0156	0,0918	< 0,00001	< 0,00001	< 0,00001	0,0519		
	r ²	0.030	0.014	0.300	0.189	0.163	0.012		
PND	Rho	0,1582	0,2425	0,0711	0,1798	0,1933	0,3658	0,2776	
	p-value	0,0365	0,0012	0,3496	0,0173	0,0108	< 0,00001	0,0002	
	r ²	0.017	0.060	0.003	0.027	0.038	0.101	0.082	
PPQ	Rho	0,036	0,0478	-0,0203	-0,0766	-0,06	0,2988	0,1234	0,4672
	p-value	0,6336	0,5263	0,7881	0,3094	0,4288	0,0001	0,1007	< 0,00001
	r ²	< 0.001	0.002	< 0.001	0.001	0.001	0.096	0.029	0.230

Table 3 Isolates with high IC₅₀ to at least one anti-malarial drug among the 181 isolates tested

Isolates origin	IC ₅₀ in nM								
	PND	PPQ	CQ	QN	MQ	MDAQ	LMF	DHA	AS
Mali	ND	175	22	185	23.4	44.8	25.8	1.2	2.0
Comoros	ND	177.5	130	460	27.6	76.4	15.8	1.2	3.2
Cameroon	15.0	189	171	217	8.0	16.3	7.0	2.0	1.9
Africa	28.4	217.3	1029	580	31.3	240.0	17.7	1.6	1.3
Côte d'Ivoire	31.2	172.8	60	377	68.0	4.6	58.0	5.3	4.0
Comoros	34.2	83.8	108	707	4.4	40.5	20.7	3.3	2.9
Gabon	37.2	90.2	1918	580	40.7	42.8	25.1	3.4	2.9
Comoros	36.1	214	145	292	15.8	69.3	8.1	1.1	1.4
Cameroon	40.2	181.6	444	576	3.2	171	5.4	0.8	0.6
Comoros	66.0	60.2	304	176	18.5	78.9	13.1	3.5	4.6
Niger	66.3	79.9	331	393	37.4	61.0	20.1	0.7	0.5
Comoros	66.7	82.6	244	918	3.5	46.6	14.1	0.8	0.8
Benin	67.4	82.4	17	728	5.3	21.7	36.4	3.0	2.2
Comoros	69.4	46.0	246	210	5.3	82.4	6.4	1.9	1.9
Thailand	71.5	91.1	63	1131	166	34.4	114.0	21.2	16.3
Côte d'Ivoire	76.1	91.0	288	660	7.8	56.0	1.4	1.3	1.8
Comoros	80.0	82.0	321	587	32.9	47.2	6.7	2.5	3.5

High IC₅₀s are in bold
 ND: not determined

[20]. In the present study, a positive correlation was shown between PND and DHA or AS responses with a coefficient of correlation $\rho = 0.18$ and 0.19 , respectively. To suggest common mechanisms of action or resistance for two compounds, that could induce cross-resistance, the coefficient of determination must be high, such as the one for AS and DHA ($\rho = 0.84$ and $r^2 = 0.68$) corresponding to 68% of the variation in the response to DHA is explained by variation in the response to AS. A coefficient of determination of 0.027 or 0.038 means that only 2.7% and 3.8% of the variation in the response to PND is explained by variation in the response to DHA and AS. These data suggest that there is no cross-resistance between PND and artemisinin derivatives. In addition, the combination of PND and AS has undergone successful clinical evaluation in Africa [10,30]. In the present study, a positive correlation was shown between PND and CQ responses with a coefficient of correlation $\rho = 0.16$ and $r^2 = 0.017$. This means that only 1.7% of the variation in the response to PND is explained by variation in the response to CQ. These data are consistent with the efficacy of the combination of PND and AS for areas in which parasites are resistant to CQ [10,30]. There have been conflicting reports on the correlations between *P. falciparum* responses to PND and CQ. Previous studies showed weak (from 0.003 to 0.26) [20,23-25,27] to modest (0.40 and 0.46) [19,21] coefficients of determination for correlations between PND and CQ. PND appeared to be equally effective *in vitro* against 37 isolates from two areas of Thailand with different CQ resistance levels [31]. Similarly, Basco and Le Bras showed no correlation between resistance to PND and CQ for 31 isolates from Central and West Africa [32]. These results suggest that no cross-resistance exists between PND and CQ. In addition, an isolate collected in a patient who took part in trekking along the Mekong from the south of Laos to the north of Thailand showed high susceptibility to CQ and MDAQ and very low susceptibility to PND (71.5 nM), PPQ (91.1 nM), QN (1,131 nM), MQ (166 nM), LMF (114 nM) and to the artemisinin derivatives DHA (21.2 nM) and AS (16.3 nM) [33]. This multi-resistant isolate was suspected of being resistant to ACT. All of the other significant positive correlations between PND and QN, MDAQ or LMF are too low ($\rho < 0.37$, $r^2 < 0.10$) to suggest cross-resistance between PND and quinoline drugs. This absence of cross-resistance may be explained by the absence of association between PND and genes involved in quinoline resistance, such as *pfprt*, *pfmdr1*, *pfmrp* or *pfhe-1* [20].

The highest coefficient of correlation was observed between PND and PPQ ($\rho = 0.47$ and $r^2 = 0.23$). This means that 23% of the variation in the response to PND is explained by variation in the response to PPQ. This

result is also too low to suggest cross-resistance between the two drugs. This result was in accordance with previous data ($r^2 = 0.20$) [27].

In vitro drug interaction between PPQ and artemisinin derivatives was indifferent or antagonistic [34-37]. However, PPQ has been combined with DHA and it has undergone successful clinical evaluation in Africa, Asia and South America [9,38-40]. In addition, PPQ-DHA is also effective to treat *P. vivax* malaria [41]. But unfortunately clinical failures to PPQ have been reported in areas of China where it has been deployed in monotherapy for *P. falciparum* [42].

The IC_{50} values for PPQ ranged from 11.8 to 217.3 nM (geometric mean = 66.8 nM, CI95% 61.8-72.3). These data are in accordance with previous studies on *P. falciparum* strains [35,43] or isolates from Cameroon (geometric mean = 39 nM) [44], Thai-Burmese border (49 nM) [45] and Kenya (50 nM) [46], but superior to geometric mean of isolates from Uganda (6.1 nM) [47], Indonesia (21.8 nM) [48] or Papua New Guinea [49]. The isolate with the highest IC_{50} to PPQ (217.3 nM) was also resistant to CQ (1029 nM) and MDAQ (240 nM).

Encouragingly, PPQ has not shown any correlation with the other quinoline drugs, i.e. CQ, QN, MDAQ, LMF or MQ. These results suggest that no cross-resistance exists between PPQ and CQ and the other quinoline anti-malarial drugs. These data are in accordance with previous studies, which showed weak coefficients of determination included between 0.015 and 0.14 for correlation between PPQ and CQ [43,45-47]. No significant correlation was identified between PPQ and DHA or AS. These data are in accordance with previous results [47]. PPQ has shown no cross-resistance with any of the anti-malarial drug tested. The absence of cross-resistance may be explained by the absence of association between PPQ and genes involved in quinoline resistance, such as *pfprt*, *pfmdr1*, *pfmrp* or *pfhe-1* [43]. A copy number variation event on chromosome 5 could be associated with PPQ resistance [50]. Transgene expression studies are underway with individual genes in this segment to evaluate their contribution to PPQ resistance.

DHA-PPQ is an inexpensive, safe and highly effective treatment for uncomplicated *falciparum* and *vivax* malaria [41,51,52]. DHA-PPQ seems to offer a better post-treatment prophylactic effect following therapy compared with artemether-LMF [6,53,54] or AS-amodiaquine [55]. The significant lower risk of recurrent parasitaemia after treatment with DHA-PPQ is likely to be explained by differences in pharmacokinetics of the non-artemisinin partner drugs. PPQ, a bisquinoline, is estimated to have elimination half-life of 17-33 days [38,56,57] while LMF and MDAQ have an estimated

elimination half-life of two to six days and one-10 days [58], respectively.

The PND-AS combination (Pyramax[®]) is one of the latest ACT combinations currently under development by the not-for-profit organisation Medicines for Malaria Venture (Geneva, Switzerland) and the pharmaceutical company Shin Poong Pharmaceuticals (Seoul, Republic of Korea) for the treatment of uncomplicated *P. falciparum* malaria and for the blood stages of *P. vivax* malaria. Pyramax[®] has recently completed phase III trials in humans. A five-day regimen of PND alone (total dose = 1800 mg) produced a better cure rate than AS, artemether or MQ used alone in the same conditions in Thailand [21]. Efficacy of PND-AS was non-inferior to that of artemether-LMF for treatment of uncomplicated *falciparum* malaria in Africa and South-east Asia [10].

Conclusions

In this study, the excellent *in vitro* anti-malarial activities of the ACT components PPQ and PND on *P. falciparum* were confirmed. The absence of cross-resistance with quinolones and artemisinin derivatives confirmed the relevant use of the combinations of PPQ and DHA or PND and AS in areas where parasites are resistant to conventional anti-malarial drugs.

Acknowledgements

The authors thank R Amalvict, E Baret, S Charras from IRBA for technical support. This work was supported by the Direction Centrale du Service de Santé des Armées, the Institut de Veille Sanitaire and Medicines for Malaria Venture.

Author details

¹Unité de Recherche en Biologie et Epidémiologie Parasitaires Unité de Recherche pour les Maladies Infectieuses et Tropicales Emergentes UMR-6236, Institut de Recherche Biomédicale des Armées, Allée du Médecin-colonel Jamot, BP 60109, 13262 Marseille Cedex, France. ²Centre National de Référence du Paludisme, Marseille, France. ³Institut Hospitalo-Universitaire en Maladies Infectieuses et Tropicales, Hôpital Nord, Marseille, France. ⁴Laboratoire de Parasitologie-Mycologie, Centre Hospitalier Universitaire de Rangueil, Toulouse, France. ⁵Service de Pathologie Infectieuse et Tropicale, Hôpital d'Instruction des Armées Laveran, Marseille, France. ⁶Travel Clinics and Division of Tropical Medicine and Imported Diseases, Centre Hospitalier Universitaire, Bordeaux, France. ⁷Malaria Research Unit, UMR 5246, CNRS Lyon, France. ⁸Laboratoire de Parasitologie-Mycologie, Hôpital de l'Archevêque, Nice, France. ⁹Laboratoire de Parasitologie-Mycologie, Centre Hospitalier Universitaire Lapeyronnie, Montpellier, France. ¹⁰Laboratoire de Parasitologie-Mycologie, Centre Hospitalier Universitaire et Université de Grenoble 1, Grenoble, France. ¹¹Laboratoire de Parasitologie-Mycologie, Centre Hospitalier Universitaire La Timone, Marseille, France. ¹²Fédération des Laboratoires, Hôpital d'Instruction des Armées Sainte Anne, Toulon, France. ¹³Service de Bactériologie-Virologie-Parasitologie, Centre Hospitalier Universitaire Caremeau, Nîmes, France. ¹⁴Medicines for Malaria Venture, Geneva, Switzerland. ¹⁵Fulcrum Pharma (Europe) Ltd, Hemel Hempstead, UK.

Authors' contributions

AP, CR and BP conceived, designed, carried out *in vitro* testing of drug susceptibility, analysed the data and drafted the manuscript. PP, FBV, FS, DM, SP, PD, DB, DM, BF, GM and NB carried out diagnostic, monitoring patients, collected clinical and epidemiological data. CO and ED conceived, designed

and drafted the manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests. The conclusions presented in this article were not financially influenced.

Received: 17 October 2011 Accepted: 14 February 2012

Published: 14 February 2012

References

1. Le Bras J, Musset L, Clain J: **Antimalarial drug resistance.** *Med Mal Infect* 2006, **36**:401-405.
2. White NJ: **Preventing antimalarial drug resistance through combinations.** *Drug Resist Update* 2001, **1**:3-9.
3. Eastman RT, Fidock DA: **Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria.** *Nat Rev Microbiol* 2009, **7**:864-874.
4. Von Seidlein L, Milligan P, Pinder M, Bojang K, Anyalebechi C, Gosling R, Coleman R, Ude JI, Sadiq A, Duraisingh M, Warhurst D, Allouche A, Target G, Mcadam K, Greenwood B, Walraven G, Olliaro P, Doherty T: **Efficacy of artesunate plus pyrimethamine-sulphadoxine for uncomplicated malaria in the Gambian children: a double-blind, randomized, controlled trial.** *Lancet* 2000, **355**:352-357.
5. Brasseur P, Agnamey P, Gaye O, Vaillant M, Taylor WRJ, Olliaro PL: **Efficacy and safety of artesunate plus amodiaquine in routine use for the treatment of uncomplicated malaria in Casamance, southern Senegal.** *Malar J* 2007, **6**:150.
6. Yeka A, Dorsey G, Kanya MR, Talisuna A, Lugemwa M, Rwakimari JB, Staedke SG, Rosenthal PJ, Wabwire-Mangen F, Bukirwa H: **Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda.** *PLoS One* 2008, **3**:2390.
7. Ashley EA, Lwin KM, McGready R, Simon WH, Phaiphun L, Proux S, Wangseang N, Taylor W, Stepniewska K, Nawamaneerat W, Thwai KL, Barends M, Leowattana W, Olliaro P, Singhasivanon P, White NJ, Nosten F: **An open label randomized comparison of mefloquine-artesunate as separate tablets vs. a new co-formulated combination for the treatment of uncomplicated multidrug-resistant falciparum malaria in Thailand.** *Trop Med Int Health* 2006, **11**:1653-1660.
8. Owusu-Agyei S, Asante KP, Owusu R, Adjuik M, Amenga-Etego S, Dosoo DK, Gyapong J, Greenwood B, Chandramohan D: **An open label, randomised trial of artesunate + amodiaquine, artesunate + chlorproguanil-dapsone and artemether-lumefantrine for the treatment of uncomplicated malaria.** *PLoS One* 2008, **3**:2530.
9. Arinaitwe E, Sandison TG, Wanzira H, Kahuru A, Homsy J, Kalamya J, Kanya MR, Vora N, Greenhouse B, Rosenthal PJ, Tappero J, Dorsey G: **Artemether-lumefantrine versus dihydroartemisinin-piperaquine for falciparum malaria: a longitudinal, randomized trial in young Ugandan children.** *Clin Infect Dis* 2009, **49**:1629-1637.
10. Tshfu AK, Gaye O, Kayentao K, Thompson R, Bhatt KM, Sesay SSS, Bustos DG, Tjitra E, Bedu-Addo G, Borghini-Fuhrer I, Duparc S, Sik Shin C, Fleckenstein L: **Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether-lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial.** *Lancet* 2010, **375**:1457-1467.
11. Carrara VI, Zwang J, Ashley EA, Price RN, Stepniewska K, Barends M, Brockman A, Anderson T, McGready R, Phaiphun L, Proux S, van Vugt M, Hutagalung R, Lwin KM, Phyo AP, Preechapornkul P, Imwong M, Pukrittayakamee S, Singhasivanon P, White NJ, Nosten F: **Changes in the treatment responses to artesunate-mefloquine on the Northwestern border of Thailand during 13 years of continuous deployment.** *PLoS One* 2009, **4**:4451.
12. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NPJ, Lindergardh N, Socheat D, White NJ: **Artemisinin resistance in Plasmodium falciparum malaria.** *N Engl J Med* 2009, **361**:455-467.
13. Noedl H, Se Y, Schaefer K, Smith BL, Socheat D, Fukuda MM: **Evidence of artemisinin-resistant malaria in western Cambodia.** *N Engl J Med* 2008, **359**:2619-2620.

14. Rogers WO, Sem R, Tero T, Chim P, Lim P, Muth S, Socheat D, Arley F, Wongsrichanalai C: **Failure of artesunate-mefloquine combination therapy for uncomplicated *Plasmodium falciparum* malaria in southern Cambodia.** *Malar J* 2009, **8**:10.
15. Nawaz F, Nsobya SL, Kiggundu M, Jobola M, Rosenthal PJ: **Selection of parasites with diminished drug susceptibility by amodiaquine-containing antimalarial regimens in Uganda.** *J Infect Dis* 2009, **200**:1650-1657.
16. Embros C, Vanderberg JP: **Synchronization of *Plasmodium falciparum* erythrocytic stages in culture.** *J Parasitol* 1979, **65**:418-420.
17. Bogreau H, Renaud F, Bouchiba H, Durand P, Assi SB, Henry MC, Garnotel E, Pradines B, Fusai T, Wade B, Adehossi E, Parola P, Kamil MA, Pujjalon O, Rogier C: **Genetic diversity and structure of African *Plasmodium falciparum* populations in urban and rural areas.** *Am J Trop Med Hyg* 2006, **74**:953-959.
18. Henry M, Diallo I, Bordes J, Ka S, Pradines B, Diatta B, M' Baye PS, Sane M, Thiam M, Gueye PM, Wade B, Touze JE, Debonne JM, Rogier C, Fusai T: **Urban malaria in Dakar, Senegal: chemosusceptibility and genetic diversity of *Plasmodium falciparum* isolates.** *Am J Trop Med Hyg* 2006, **75**:146-151.
19. Elueze EI, Croft SL, Warhurst DC: **Activity of pyronaridine and mepacrine against twelve strains of *Plasmodium falciparum* in vitro.** *J Antimicrob Chemother* 1996, **37**:511-518.
20. Pradines B, Briolant S, Henry M, Oeuvray C, Baret E, Amalvict R, Didillon E, Rogier C: **Absence of association between pyronaridine in vitro responses and polymorphisms in genes involved in quinoline resistance in *Plasmodium falciparum*.** *Malar J* 2010, **9**:337.
21. Looareesuwan S, Kyle DE, Vivaran C, Vanijanonta S, Wilairatana P, Wernsdorfer WH: **Clinical study of pyronaridine for the treatment of acute uncomplicated falciparum malaria in Thailand.** *Am J Trop Med Hyg* 1996, **54**:205-209.
22. Ringwald P, Moukoko Eboumbou CE, Bickii J, Basco LK: **In vitro activities of pyronaridine, alone and in combination with other antimalarial drugs, against *Plasmodium falciparum*.** *Antimicrob Agents Chemother* 1999, **43**:1525-1527.
23. Kurth F, Pongratz P, B elard S, Mordm uller B, Kreamsner PG, Ramharter M: **In vitro activity of pyronaridine against *Plasmodium falciparum* and comparative evaluation of anti-malarial drug susceptibility assays.** *Malar J* 2009, **8**:79.
24. Pradines B, Tall A, Parzy D, Spiegel A, Fusai T, Hienne R, Trape JF, Doury JC: **In vitro activity of pyronaridine and amodiaquine against African isolates (Senegal) of *Plasmodium falciparum* in comparison with standard antimalarial agents.** *J Antimicrob Chemother* 1998, **42**:333-339.
25. Pradines B, Mabika Mamfoumbi M, Parzy D, Owono Medang M, Lebeau C, Mourou Mbina JR, Doury JC, Kombila M: **In vitro susceptibility of African isolates of *Plasmodium falciparum* from Gabon to pyronaridine.** *Am J Trop Med Hyg* 1999, **60**:105-108.
26. Pradines B, Tall A, Ramiandrasoa F, Spiegel A, Sokhna C, Fusai T, Mosnier J, Daries W, Trape JF, Kunesch G, Parzy D, Rogier C: **In vitro activity of iron-binding compounds against Senegalese isolates of *Plasmodium falciparum*.** *J Antimicrob Chemother* 2006, **57**:1093-1099.
27. Price RN, Marfurt J, Chalfein F, Kenagalem E, Piera KA, Tjitra E, Anstey NM, Russel B: **In vitro activity of pyronaridine against multidrug-resistant *Plasmodium falciparum* and *Plasmodium vivax*.** *Antimicrob Agents Chemother* 2010, **54**:5146-5150.
28. Davis TM, Hamzah J, Ilett KF, Karunajeewa HA, Reeder JC, Batty KT, Hackett S, Barrett PHR: **In vitro interactions between piperazine, dihydroartemisinin, and other conventional and novel antimalarial drugs.** *Antimicrob Agents Chemother* 2006, **50**:2883-2885.
29. Vivas L, Rattray L, Stewart L, Bongard E, Robinson BL, Peters W, Croft SL: **Anti-malarial efficacy of pyronaridine and artesunate in combination in vitro and in vivo.** *Acta Trop* 2008, **105**:222-228.
30. Ramharter M, Kurth F, Schreier AC, Nemeth J, Glasenapp I, B elard S, Schlie M, Kammer J, Koumba PK, Cisse B, Mordm uller B, Lell B, Issifou S, Oeuvray C, Fleckenstein L, Kreamsner PG: **Fixed-dose pyronaridine-artesunate combination for treatment of uncomplicated falciparum malaria in pediatric patients in Gabon.** *J Infect Dis* 2008, **198**:911-919.
31. Childs GE, Hausler B, Milhous W, Chen C, Wimonwattawatee T, Pooyindee N, Boudreau EF: **In vitro activity of pyronaridine against field isolates and reference clones of *Plasmodium falciparum*.** *Am J Trop Med Hyg* 1988, **38**:24-29.
32. Basco LK, Le Bras J: **In vitro activity of pyronaridine against African strains of *Plasmodium falciparum*.** *Ann Trop Med Parasitol* 1992, **86**:447-454.
33. Pradines B, Bertaux L, Pomares C, Delaunay P, Marty P: **Reduced in vitro susceptibility to artemisinin derivatives associated with multi-resistance in a traveller returning from South-East Asia.** *Malar J* 2011, **10**:268.
34. Davis TME, Hamzah J, Ilett KF, Karunajeewa HA, Reeder JC, Batty KT, Hackett S, Barrett PHR: **In vitro interactions between piperazine, dihydroartemisinin, and other conventional and novel antimalarial drugs.** *Antimicrob Agents Chemother* 2006, **50**:2883-2885.
35. Fivelman QL, Adagu IS, Warhurst DC: **Effects of piperazine, chloroquine, and amodiaquine on drug uptake and of these in combination with dihydroartemisinin against drug-sensitive and -resistant *Plasmodium falciparum* strains.** *Antimicrob Agents Chemother* 2007, **51**:2265-2267.
36. Muangnoicharoen S, Johnson DJ, Looareesuwan S, Krudsood S, Ward SA: **Role of known molecular markers of resistance in the antimalarial potency of piperazine and dihydroartemisinin in vitro.** *Antimicrob Agents Chemother* 2009, **53**:1362-1366.
37. Snyder C, Chollet J, Santo-Tomas J, Scheurer C, Wittlin S: **In vitro and in vivo interaction of synthetic peroxide RBx11160 (OZ277) with piperazine in *Plasmodium* models.** *Exp Parasitol* 2007, **115**:296-300.
38. Tarning J, Ashley EA, Lindegardh N, Stepniewska K, Phaiphun L, Day NPJ, McGready R, Ashton M, Nosten F, White NJ: **Population pharmacokinetics of piperazine after two different treatment regimens with dihydroartemisinin-piperazine in patients with *Plasmodium falciparum* malaria in Thailand.** *Antimicrob Agents Chemother* 2008, **52**:1052-1061.
39. Valecha N, Pyae Phyo A, Mayxay M, Newton PN, Krudsood S, Keomany S, Khanthavong M, Pongvongsa T, Ruangveerayuth R, uthaisil C, Ubben D, Duparc S, Bacchieri A, Corsi M, Rao BHK, Bhattacharya PC, Dubhashi N, Ghosh SK, Dev V, Kumar A, Pukittayakamee S: **An open-label, randomized study of dihydroartemisinin-piperazine versus artesunate-mefloquine for falciparum malaria in Asia.** *PLoS One* 2010, **5**:11880.
40. Grande T, Bernasconi A, Erhart A, Gamboa D, Casapia M, Delgado C, Torres K, Fanello C, Llanos-Cuentas A, D'Alessandro U: **A randomized controlled trial to assess the efficacy of dihydroartemisinin-piperazine for the treatment of uncomplicated falciparum malaria in Peru.** *PLoS One* 2007, **10**:1101.
41. Awab GR, Pukittayakamee S, Imwong M, Dondorp AM, Woodrow CJ, Lee SJ, Day NPJ, Singhasivanon P, White NJ, Kaker F: **Dihydroartemisinin-piperazine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial.** *Malar J* 2010, **9**:105.
42. Davis TM, Hung TY, Sim IK, Karunajeewa HA, Ilett KF: **Piperazine: a resurgent antimalarial drug.** *Drugs* 2005, **65**:75-87.
43. Briolant S, Henry M, Oeuvray C, Amalvict R, Baret E, Didillon E, Rogier C, Pradines B: **Absence of association between piperazine in vitro responses and polymorphisms in the *pfcr*, *pfmdr1*, *pfmrp*, and *pfhr* genes in *Plasmodium falciparum*.** *Antimicrob Agents Chemother* 2010, **54**:3537-3544.
44. Basco LK, Ringwald P: **In vitro activity of piperazine and other 4-aminoquinolines against clinical isolates of *Plasmodium falciparum* in Cameroon.** *Antimicrob Agents Chemother* 2003, **47**:1391-1394.
45. Barends M, Jaidee A, Khaohirun N, Singhasivanon P, Nosten F: **In vitro activity of ferroquine (SSR 97193) against *Plasmodium falciparum* isolates from the Thai-Burmese border.** *Malar J* 2007, **6**:81.
46. Mwai L, Kiara SM, Abdurahman A, Pole L, Rippert A, Diriye A, Bull P, Marsh K, Borrmann S, Nzila A: **In vitro activities of piperazine, lumefantrine, and dihydroartemisinin in Kenyan *Plasmodium falciparum* isolates and polymorphisms in *pfcr* and *pfmdr1*.** *Antimicrob Agents Chemother* 2009, **55**:5069-5073.
47. Nsobya SL, Kiggundu M, Nanyunja S, Jobola M, Greenhouse B, Rosenthal PJ: **In vitro sensitivities of *Plasmodium falciparum* to different antimalarial drugs in Uganda.** *Antimicrob Agents Chemother* 2010, **54**:1200-1206.
48. Marfurt J, Chalfein F, Prayoga P, Wabiser F, Kenagalem E, Piera KA, MacHunter B, Tjitra E, Anstey NM, Price RN: **Ex vivo drug susceptibility of ferroquine against chloroquine-resistant isolates of *Plasmodium falciparum* and *P. vivax*.** *Antimicrob Agents Chemother* 2011, **55**:4461-4464.
49. Wong RP, Lautu D, Tavul L, Hackett SL, Siba P, Karunajeewa HA, Ilett KF, Mueller I, Davis TM: **In vitro sensitivity of *Plasmodium falciparum* to conventional and novel antimalarial drugs in Papua New Guinea.** *Trop Med Int Health* 2010, **15**:342-349.
50. Eastman RT, Dharia NV, Winzeler EA, Fidock DA: **Piperazine resistance is associated with a copy number variation on chromosome 5 in drug-**

- pressured *Plasmodium falciparum* parasites. *Antimicrob Agents Chemother* 2011, **55**:3908-3916.
51. Myint HY, Ashley EA, Day NPJ, Nosten F, White NJ: **Efficacy and safety of dihydroartemisinin-piperaquine.** *Trans R Soc Trop Med Hyg* 2007, **101**:858-866.
 52. Price RN, Hasugian AR, Ratcliff A, Siswanto H, Purba HLE, Kenangalem E, Lindegardh N, Penttinen P, Laihah F, Ebsworth EP, Anstey NM, Tjitra E: **Clinical and pharmacological determinants of the therapeutic response to dihydroartemisinin-piperaquine for drug-resistant malaria.** *Antimicrob Agents Chemother* 2007, **51**:4090-4097.
 53. Kanya MR, Yeka A, Burkirwa H, Lugemwa M, Rwakimari JB, Staedke SG, Talisuna AO, Greenhouse B, Nosten F, Rosenthal PJ, Wabwire-Mangen F, Dorsey G: **Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: a randomized trial.** *Plos Clin Trials* 2007, **2**:20.
 54. Zongo I, Dorsey G, Rouamba N, Dokomajilar C, Séré Y, Rosenthal PJ, Ouédraogo JB: **Randomized comparison of amodiaquine plus sulfadoxine-pyrimethamine, artemether-lumefantrine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated *Plasmodium falciparum* malaria in Burkina-Faso.** *Clin Infect Dis* 2007, **45**:1453-1461.
 55. Hasugian AR, Purba HLE, Kenangalem E, Wuwung RM, Ebsworth EP, Maristela R, Penttinen PMP, Laihah F, Anstey NM, Tjitra E, Price RN: **Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug resistant *Plasmodium falciparum* and *Plasmodium viva* malaria.** *Clin Infect Dis* 2008, **44**:1067-1074.
 56. Karunajeewa HA, Ilett KF, Mueller I, Siba P, Law I, Page-Sharp M, Lin E, Lammey J, Batty KT, Davis TME: **Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria.** *Antimicrob Agents Chemother* 2008, **52**:237-243.
 57. Tarning J, Lindegardh N, Annerberg A, Singtoroj T, Day NPJ, Ashton M, White NJ: **Pitfalls in estimating piperaquine elimination.** *Antimicrob Agents Chemother* 2005, **49**:5127-5128.
 58. Ezzet F, Mull R, Karbwang J: **Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients.** *Br J Clin Pharmacol* 1998, **46**:553-561.

doi:10.1186/1475-2875-11-45

Cite this article as: Pascual *et al.*: *Ex vivo* activity of the ACT new components pyronaridine and piperaquine in comparison with conventional ACT drugs against isolates of *Plasmodium falciparum*. *Malaria Journal* 2012 **11**:45.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

